Fig. 5. Patients that clinically benefited from OMO-103 showed low baseline levels of MIP-1β, IL-8, CD62E and GM-CSF, with model pairings of different soluble factors providing outstanding outcome predictors.
a–c, Levels of soluble factors were measured in patient serum samples at pretreatment using the Luminex technique. a,b, Nine patients with PD and seven with SD were included in the analyses. a, Patients showing disease stabilization at cycle 3 displayed significantly lower levels of MIP-1β, IL-8, CD62E and GM-CSF compared with those with PD (median shown). A two-sided Mann–Whitney U-test, with no adjustment for multiple comparisons, was used for statistical analysis. b, Binomial logistic regression analysis of the association of cytokine and chemokine levels at pretreatment with the probability of disease stabilization. ORs of soluble factors in patients are shown in the forest plot (left) and summary table (right); mean and CI are shown. c, Soluble factor combination models generated using QLattice technology; data from nine patients with PD and six with SD were used to generate the models. Plots of combination models CD62E + MIP-1β, MCP-1 + MIP-1β and CD62E + IL-8 are shown in relationship to patient response. SD and PD are indicated by pink and green dots, respectively. Colored lines correspond to confidence bands: blue indicates the mean, orange 95% CI and yellow 5% CI. Patient no. 101-009 is marked with a rhombus because their data were not available at the time of generation of the models and were later included.